About the Osteoarthritis Pain Drugs Market
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.
Technavio’s analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Abbott Laboratories
• Johnson & Johnson
• Novartis International
• Pfizer

Other prominent vendors
• AbbVie
• Abiogen Pharma
• Afferent Pharmaceuticals
• Astellas Pharma
• BioDelivery Sciences International
• Crystal Genomics
• Cytori Therapeutics
• Daiichi Sankyo
• Eli Lilly
• Endo Pharmaceuticals Holdings
• Horizon Pharma
• iCeutica
• Iroko Pharmaceuticals
• Merck
• Nuvo Research
• Regeneron Pharmaceuticals
• Sanofi
• SantoSolve
• Techfields Pharma
• Winston Pharmaceuticals
• Yooyoung Pharmaceutical
• Zynerba Pharmaceuticals

Market driver
• Significant unmet medical needs
• For a full, detailed list, view our report

Market challenge
• Preference for alternative therapies
• For a full, detailed list, view our report

Market trend
• Emergence of new treatments
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.